A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their Infants

Active, not recruitingOBSERVATIONAL

Enrollment

2,961

Participants

Timeline

Start Date

March 16, 2021

Primary Completion Date

March 31, 2031

Study Completion Date

August 31, 2031

Conditions

Multiple Sclerosis

Interventions

DRUG

Ozanimod

Women with MS who were exposed to ozanimod during pregnancy

DRUG

Select DMTs other than ozanimod

Women with MS exposed to select DMTs other than ozanimod during pregnancy

DRUG

No DMTs

Women with MS not exposed to any DMTs during pregnancy

Trial Locations (1)

OptumInsight Life Sciences Inc, Eden Prairie